Bibliographies Recherches dans les pays à ressources limitées 2014

Aghokeng A F, Monleau M, Eymard-Duvernay S, Dagnra A, Kania D, Ngo-Giang-Huong N, Toni T D, Toure-Kane C, Truong L X, Delaporte E, Chaix M L, Peeters M, Ayouba A and Group A S. Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia. *Clin Infect Dis*, 2014, 58, 99-109 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, ANRS 12186

April M D, Wood R, Berkowitz B K, Paltiel A D, Anglaret X, Losina E, Freedberg K A and Walensky R P. The survival benefits of antiretroviral therapy in South Africa. *J Infect Dis*, 2014, 209, 491-9 The Journal of infectious diseases,

Barennes H, Guillet S, Limsreng S, Him S, Nouhin J, Hak C, Srun C, Viretto G, Ouk V, Delfraissy J F and Segeral O. Virological failure and HIV-1 drug resistance mutations among naive and antiretroviral pre-treated patients entering the ESTHER program of Calmette Hospital in Cambodia. *PLoS One*, 2014, 9, e105736 PloS one, Site Cambodge

Bastard M, Fall M B and groupe d'etude de la Cohorte A. [Long term adherence to HAART in Senegal]. *Bull Soc Pathol Exot*, 2014, 107, 241-3 Bulletin de la Societe de pathologie exotique, ANRS 1215

Bertrand J, Verstuyft C, Chou M, Borand L, Chea P, Nay K H, Blanc F X, Mentre F, Taburet A M and Group C S. Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. *J Infect Dis*, 2014, 209, 399-408 The Journal of infectious diseases, ANRS 12154

Bhatt N B, Barau C, Amin A, Baudin E, Meggi B, Silva C, Furlan V, Grinsztejn B, Barrail-Tran A, Bonnet M, Taburet A M and Group A C S. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. *Antimicrob Agents Chemother*, 2014, 58, 3182-90 Antimicrobial agents and chemotherapy,

Bhatt N B, Baudin E, Meggi B, da Silva C, Barrail-Tran A, Furlan V, Grinsztejn B, Bonnet M, Taburet A M and on behalf of the A C S G. Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship. *J Antimicrob Chemother*, 2014 The Journal of antimicrobial chemotherapy,

Bonnard P, Elsharkawy A, Zalata K, Delarocque-Astagneau E, Biard L, Le Fouler L, Hassan A B, Abdel-Hamid M, El-Daly M, Gamal M E, El Kassas M, Bedossa P, Carrat F, Fontanet A and Esmat G. Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt. *J Viral Hepat*, 2014 Journal of viral hepatitis, ANRS 12184

Borand L, Madec Y, Laureillard D, Chou M, Marcy O, Pheng P, Prak N, Kim C, Lak K K, Hak C, Dim B, Nerrienet E, Fontanet A, Sok T, Goldfeld A E, Blanc F X and Taburet A M. Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial). *PLoS One*, 2014, 9, e90350 PloS one, ANRS1295 / ANRS 12160 CAMELIA

Boufkhed S and Taverne B. [Assessing the direct cost of medical care for HIV between the third and tenth year of ARV treatment in Dakar]. *Bull Soc Pathol Exot*, 2014, 107, 292-8 Bulletin de la Societe de pathologie exotique, ANRS 1215

Boulle C, Rouet F, Fassinou P, Msellati P, Debeaudrap P, Chaix M L, Rouzioux C and Avettand-Fenoel V. HIV-1 DNA concentrations and evolution among African HIV-1-infected children under antiretroviral treatment (ANRS 1244/1278). *J Antimicrob Chemother*, 2014, 69, 3047-50 The Journal of antimicrobial chemotherapy, ANRS1244/ANRS1278

Breban R, Arafa N, Leroy S, Mostafa A, Bakr I, Tondeur L, Abdel-Hamid M, Doss W, Esmat G, Mohamed M K and Fontanet A. Effect of preventive and curative interventions on hepatitis C virus transmission in Egypt (ANRS 1211): a modelling study. *The Lancet. Global health*, 2014, 2, e541-9 The Lancet. Global health, ANRS 1211

Breban R and Fontanet A. Feasible HCV targets in Egypt - authors' reply. *The Lancet. Global health*, 2014, 2, e688 The Lancet. Global health, Site Egypte

Cames C, Cournil A, de Vincenzi I, Gaillard P, Meda N, Luchters S, Nduati R, Naidu K, Newell M L, Read J S, Bork K and Kesho Bora Study G. Postpartum weight change among HIV-infected mothers by antiretroviral prophylaxis and infant feeding modality in a research setting. *AIDS*, 2014, 28, 85-94 Aids, ANRS 1289 KESHO BORA

Cassier M and Correa M. Access to medicines in developing countries: ethical demands and moral economy. *Developing world bioethics*, 2014, 14, ii-viii Developing world bioethics,

Cianci F, Sweeney S, Konate I, Nagot N, Low A, Mayaud P and Vickerman P. The cost of providing combined prevention and treatment services, including ART, to female sex workers in Burkina Faso. *PLoS One*, 2014, 9, e100107 PloS one, ANRS 1222

Couderc M and Desclaux Sall C. [Moving from patient information to involvement in associations for people living with HIV participating in a medical study in Senegal - ANRS cohort 1215]. *Bull Soc Pathol Exot*, 2014, 107, 286-91 Bulletin de la Societe de pathologie exotique, ANRS 1215

Coulibaly M, Meda N, Yonaba C, Ouedraogo S, Congo M, Barry M, Thio E, Siribie I, Koueta F, Ye D, Kam L, Blanche S, Van De Perre P, Leroy V and ANRS M S G. Missed Opportunities for Early Access to Care of HIV-Infected Infants in Burkina Faso. *PLoS One*, 2014, 9, e111240 PloS one, ANRS 12206 MONOD

Cournil A, Eymard-Duvernay S, Diouf A and groupe d'etude de la cohorte A. [Bone aging and frailty syndrome after 10 years of ARV treatment in Senegal]. *Bull Soc Pathol Exot*, 2014, 107, 238-40 Bulletin de la Societe de pathologie exotique, ANRS 1215

Cousien A, Obach D, Deuffic-Burban S, Mostafa A, Esmat G, Canva V, El Kassas M, El-Sayed M, Anwar W A, Fontanet A, Mohamed M K and Yazdanpanah Y. Is expert opinion reliable when estimating transition probabilities? The case of HCV-related cirrhosis in Egypt. *BMC medical research methodology*, 2014, 14, 39 BMC medical research methodology, ANRS 12215

Coutherut J, Desclaux A and Groupe d'etude A. [Disclosing HIV status: the experience of PLHIV after 10 years of ARV treatment in Senegal]. *Bull Soc Pathol Exot*, 2014, 107, 266-72 Bulletin de la Societe de pathologie exotique, ANRS 1215

Coutherut J and groupe d'etude de la cohorte A. [Socio-economic impact of one decade of ARV therapy for people living with HIV in Senegal]. *Bull Soc Pathol Exot*, 2014, 107, 261-5 Bulletin de la Societe de pathologie exotique, ANRS 1215

Danel C, Kabran M, Inwoley A, Badje A, Herrmann J L, Moh R, Lecarrou J, Gabillard D, Ntakpe J B, Deschamps N, Ouattara E, Perronne C, Eholie S and Anglaret X. Quantiferon-TB Gold: performance for ruling out active tuberculosis in HIV-infected adults with high CD4 count in Cote d'Ivoire, West Africa. *PLoS One*, 2014, 9, e107245 PloS one, ANRS 12224

De Beaudrap P, Diouf A, Bousso Niang K and groupe d'etude de la Cohorte A. [Clinical and biological effectiveness of antiretroviral therapy in the ANRS 1215 cohort]. *Bull Soc Pathol Exot*, 2014, 107, 230-3 Bulletin de la Societe de pathologie exotique, ANRS 1215

Desclaux A. After the withdrawal of 'informed choice': the meanings and social effects of mothers' choice for HIV prevention in Senegal. *Anthropology & medicine*, 2014, 21, 113-24 Anthropology & medicine, ANRS 12271

Desclaux A, Boye S, Sow K and Ndoye T. [Experience of people living with HIV (PLHIV) on chronic disease: a typology]. *Bull Soc Pathol Exot*, 2014, 107, 244-5 Bulletin de la Societe de pathologie exotique, ANRS 1215

Desclaux A, Boye S and Taverne B. [The social relegation of widows living with HIV in the time of ART in Senegal]. *Bull Soc Pathol Exot*, 2014, 107, 273-8 Bulletin de la Societe de pathologie exotique, ANRS 1215

Desclaux A and Sow A. [Non-adaptation of people living with HIV (PLHIV) associations to people over 50]. *Bull Soc Pathol Exot*, 2014, 107, 279-80 Bulletin de la Societe de pathologie exotique, ANRS 1215

Diaw J, Taverne B and Coutherut J. [Sexual complaints and dysfunction among PLHIV receiving ARV treatment for ten years in Senegal]. *Bull Soc Pathol Exot*, 2014, 107, 258-60 Bulletin de la Societe de pathologie exotique, ANRS 1215

Diouf A, Cournil A and groupe d'etude de la Cohorte A. [Prevalence of metabolic complications after 10 years of antiretroviral treatment in Senegal]. *Bull Soc Pathol Exot*, 2014, 107, 234-7 Bulletin de la Societe de pathologie exotique, ANRS 1215

Duffy D, Mamdouh R, Laird M, Soneson C, Le Fouler L, El-Daly M, Casrouge A, Decalf J, Abbas A, Eldin N S, Fontes M, Abdel-Hamid M, Mohamed M K, Rafik M, Fontanet A and Albert M L. The ABCs of viral hepatitis that define biomarker signatures of acute viral hepatitis. *Hepatology*, 2014, 59, 1273-82 Hepatology, ANRS 12210

Eholie S P, Vella S and Anglaret X. Commentary: Antiretroviral therapy initiation criteria in low resource settings--from 'when to start' to 'when not to start'. *AIDS*, 2014, 28 Suppl 2, S101-4 Aids, ANRS 12136

Ekouevi D K, Tchounga B K, Coffie P A, Tegbe J, Anderson A M, Gottlieb G S, Vitoria M, Dabis F and Eholie S P. Antiretroviral therapy response among HIV-2 infected patients: a systematic review. *BMC Infect Dis*, 2014, 14, 461 BMC infectious diseases,

Feray C, Bouscaillou J, Falissard B, Mohamed M K, Arafa N, Bakr I, El-Hoseiny M, Daly M E, El-Kafrawy S, Plancoulaine S, Abdel-Hamid M, Thiers V and Fontanet A. A novel method to identify routes of hepatitis C virus transmission. *PLoS One*, 2014, 9, e86098 PloS one, ANRS 1211 ANRS 12107

Goyet S, Lerolle N, Fournier-Nicolle I, Ken S, Nouhin J, Sowath L, Barennes H, Hak C, Ung C, Viretto G, Delfraissy J F, Khuon P and Segeral O. Risk factors for hepatitis C transmission in HIV patients, Hepacam study, ANRS 12267 Cambodia. *AIDS Behav*, 2014, 18, 495-504 AIDS and behavior, ANRS 12267 HEPACAM

Grinsztejn B, De Castro N, Arnold V, Veloso V G, Morgado M, Pilotto J H, Brites C, Madruga J V, Barcellos N T, Santos B R, Vorsatz C, Fagard C, Santini-Oliveira M, Patey O, Delaugerre C, Chene G, Molina J M and group A R T s. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. *Lancet Infect Dis*, 2014, 14, 459-67 The Lancet. Infectious diseases,

Jean K, Gabillard D, Moh R, Danel C, Desgrees-du-Lou A, N'Takpe J B, Le Carrou J, Badje A, Eholie S, Lert F, Anglaret X and Dray-Spira R. Decrease in sexual risk behaviours after early initiation of antiretroviral therapy: a 24-month prospective study in Cote d'Ivoire. *J Int AIDS Soc*, 2014, 17, 18977 Journal of the International AIDS Society, ANRS 12239

Jean K, Gabillard D, Moh R, Danel C, Fassassi R, Desgrees-du-Lou A, Eholie S, Lert F, Anglaret X and Dray-Spira R. Effect of early antiretroviral therapy on sexual behaviors and HIV-1 transmission risk among adults with diverse heterosexual partnership statuses in Cote d'Ivoire. *J Infect Dis*, 2014, 209, 431-40 The Journal of infectious diseases, ANRS 12239

Kania D, Ottomani L, Meda N, Peries M, Dujols P, Bollore K, Renier W, Viljoen J, Ducos J, Van de Perre P and Tuaillon E. Performance of two real-time PCR assays for hepatitis B virus DNA detection and quantitation. *J Virol Methods*, 2014, 201, 24-30 Journal of virological methods, ANRS 12308/B 75

Kay A, Melo da Silva E, Pedreira H, Negreiros S, Lobato C, Braga W, Muwonge R, Deny P, Reis M, Zoulim F, Trepo C, D'Oliveira A, Jr., Salcedo J M, Schinoni M I and Parana R. HBV/HDV co-infection in the Western Brazilian Amazonia: an intriguing mutation among HDV genotype 3 carriers. *J Viral Hepat*, 2014, 21, 921-4 Journal of viral hepatitis, ANRS 12259

Kouame G, Danel C, Moh R, Badje A, Jean K, N'Takpe J B, Gabillard D, Le Carrou J, du Lou A D, Deschamps N, Eholie S and Anglaret X. WHO guidelines for antiretroviral therapy in serodiscordant couples in sub-Saharan Africa: how many fit?, *AIDS*, 2014, 28, 1533-5 Aids, ANRS 12136

Laird M E, Mohsen A, Duffy D, Mamdouh R, LeFouler L, Casrouge A, El-Daly M, Rafik M, Abdel-Hamid M, Soulier A, Pawlotsky J M, Hezode C, Rosa I, Renard P, Mohamed M K, Bonnard P, Izopet J, Mallet V, Pol S, Albert M L and Fontanet A. Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection. *J Hepatol*, 2014, 61, 770-6 Journal of hepatology, ANRS 12210

Lan N T, Thu N T, Barrail-Tran A, Duc N H, Lan N N, Laureillard D, Lien T T, Borand L, Quillet C, Connolly C, Lagarde D, Pym A, Lienhardt C, Dung N H, Taburet A M and Harries A D. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. *PLoS One*, 2014, 9, e84866 PloS one, ANRS 12150

Larmarange J, Balestre E, Orne-Gliemann J, Iwuji C, Okesola N, Newell M L, Dabis F and Lert F. HIV Ascertainment through Repeat Home-based Testing in the Context of a Treatment as Prevention Trial (ANRS 12249 TasP) in Rural South Africa. *AIDS Res Hum Retroviruses*, 2014, 30 Suppl 1, A287 AIDS research and human retroviruses,

Low A J, Konate I, Nagot N, Weiss H A, Kania D, Vickerman P, Segondy M, Mabey D, Pillay D, Meda N, van de Perre P, Mayaud P and Yerelon Study G. Cervicovaginal HIV-1 shedding in women taking

antiretroviral therapy in Burkina Faso: a longitudinal study. *J Acquir Immune Defic Syndr*, 2014, 65, 237-45 Journal of acquired immune deficiency syndromes, ANRS 1222

Low A J, Konate I, Nagot N, Weiss H A, Mabey D, Segondy M, Vickerman P, Meda N, van de Perre P, Mayaud P and Yerelon Cohort study g. Neisseria gonorrhoeae and Chlamydia trachomatis infection in HIV-1-infected women taking antiretroviral therapy: a prospective cohort study from Burkina Faso. *Sex Transm Infect*, 2014, 90, 100-3 Sexually transmitted infections, ANRS 1222

Marcy O, Laureillard D, Madec Y, Chan S, Mayaud C, Borand L, Prak N, Kim C, Lak K K, Hak C, Dim B, Sok T, Delfraissy J F, Goldfeld A E, Blanc F X and Team C S. Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial. *Clin Infect Dis*, 2014, 59, 435-45 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, ANRS 1295/ANRS 12160

Meresse M, March L, Kouanfack C, Bonono R C, Boyer S, Laborde-Balen G, Aghokeng A, Suzan-Monti M, Delaporte E, Spire B, Carrieri M P, Laurent C and Stratall A E S G. Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon. *HIV Med*, 2014, 15, 478-87 HIV medicine,

Monleau M, Aghokeng A F, Eymard-Duvernay S, Dagnra A, Kania D, Ngo-Giang-Huong N, Toure-Kane C, Truong L X, Chaix M L, Delaporte E, Ayouba A, Peeters M and Group A S. Field evaluation of dried blood spots for routine HIV-1 viral load and drug resistance monitoring in patients receiving antiretroviral therapy in Africa and Asia. *J Clin Microbiol*, 2014, 52, 578-86 Journal of clinical microbiology,

Muller F and Taverne B. [Representations of therapeutic failure of ARV treatment among patients and health care professionals in Dakar]. *Bull Soc Pathol Exot*, 2014, 107, 281-5 Bulletin de la Societe de pathologie exotique, ANRS 1215

Ndoye I, Taverne B and Group A c S. Twelve years of follow-up for patients treated with ARVs in Senegal (ANRS Cohort 1215): description of population and methodology. *Bull Soc Pathol Exot*, 2014, 107, 214-21 Bulletin de la Societe de pathologie exotique, ANRS 1215

Obach D, Deuffic-Burban S, Esmat G, Anwar W A, Dewedar S, Canva V, Cousien A, Doss W, Mostafa A, Pol S, Buti M, Siebert U, Fontanet A, Mohamed M K and Yazdanpanah Y. Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt. *Clin Infect Dis*, 2014, 58, 1064-71 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, ANRS 12215

Ouattara E N, Ross E L, Yazdanpanah Y, Wong A Y, Robine M, Losina E, Moh R, Walensky R P, Danel C, Paltiel A D, Eholie S P, Freedberg K A and Anglaret X. Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Cote d'Ivoire. *J Acquir Immune Defic Syndr*, 2014, 66, 294-302 Journal of acquired immune deficiency syndromes,

Peeters M, D'Arc M and Delaporte E. Origin and diversity of human retroviruses. *AIDS reviews*, 2014, 16, 23-34 AIDS reviews,

Plazy M, Dray-Spira R, Orne-Gliemann J, Dabis F and Newell M L. Continuum in HIV care from entry to ART initiation in rural KwaZulu-Natal, South Africa. *Trop Med Int Health*, 2014, 19, 680-89 Tropical medicine & international health : TM & IH, ANRS 12249 / B65

Rouet F, Kania D, Tuaillon E, Maiga A, Nouhin J, Rouzioux C, Descamps D and Plantier J C. Use of reverse transcription-PCR-based assays for quantification of HIV-1 in dried blood spots requires specific HIV-1 RNA isolation for monitoring of antiretroviral treatment efficiency. *J Clin Microbiol*, 2014, 52, 2740-1 Journal of clinical microbiology, ANRS 12186, ANRS 12235, AC12 Viro

Sanou A, Tarnagda Z, Kanyala E, Zingue D, Nouctara M, Ganame Z, Combary A, Hien H, Dembele M, Kabore A, Meda N, Van de Perre P, Neveu D, Banuls A L and Godreuil S. Mycobacterium bovis in Burkina Faso: epidemiologic and genetic links between human and cattle isolates. *PLoS neglected tropical diseases*, 2014, 8, e3142 PLoS neglected tropical diseases, ANRS 12204

Sofeu C L, Warszawski J, Ateba Ndongo F, Penda I C, Tetang Ndiang S, Guemkam G, Makwet N, Owona F, Kfutwah A, Tchendjou P, Texier G, Tchuente M, Faye A, Tejiokem M C and Group A-P S. Low birth weight in perinatally HIV-exposed uninfected infants: observations in urban settings in Cameroon. *PLoS One*, 2014, 9, e93554 PloS one, ANRS 12140, ANRS 12225

Sow K. [Childbearing in the era of antiretroviral drugs in Senegal, representations and practices among PLHIV and health care professionals]. *Bull Soc Pathol Exot*, 2014, 107, 252-7 Bulletin de la Societe de pathologie exotique, ANRS 1215

Taverne B, Desclaux A, Delaporte E and Ndoye I. [Long-term impact of antiretroviral therapy in Africa: current knowledge]. *Bull Soc Pathol Exot*, 2014, 107, 222-9 Bulletin de la Societe de pathologie exotique, ANRS 1215

Tchounga B K, Inwoley A, Coffie P A, Minta D, Messou E, Bado G, Minga A, Hawerlander D, Kane C, Eholie S P, Dabis F, Ekouevi D K and Collaboration W. Re-testing and misclassification of HIV-2 and HIV-1&2 dually reactive patients among the HIV-2 cohort of the West African Database to evaluate AIDS collaboration. *J Int AIDS Soc*, 2014, 17, 19064 Journal of the International AIDS Society, ANRS 12294-B78

Veras J. Making tenofovir accessible in the brazilian public health system: patent conflicts and generic production. *Developing world bioethics*, 2014, 14, 92-100 Developing world bioethics,

Zida S, Tarnagda Z, Kabore A, Zingue D, Hien H, Sanou A, Michel Gomgnimbou K, Nouctara M, Ouedraogo M, Ouedraogo O, Godreuil S and Meda N. [Current status of atypical mycobacterial infections in Burkina Faso: results of a regional survey]. *The Pan African medical journal*, 2014, 17, 188 The Pan African medical journal, ANRS 12204